Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

Hemophilia A (HA) and hemophilia B (HB) are X-linked bleeding disorders due to inheritable deficiencies in either coagulation factor VIII (FVIII) or factor IX (FIX), respectively. Recently, gene therapy clinical trials with adeno-associated virus (AAV) vectors and protein-engineered transgenes, B-do...

Descripción completa

Detalles Bibliográficos
Autores principales: Samelson-Jones, Benjamin J., Arruda, Valder R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349562/
https://www.ncbi.nlm.nih.gov/pubmed/30705923
http://dx.doi.org/10.1016/j.omtm.2018.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349562/
https://www.ncbi.nlm.nih.gov/pubmed/30705923
http://dx.doi.org/10.1016/j.omtm.2018.12.007

Ejemplares similares